Literature DB >> 3422113

A quantitative bioassay for HIV-1 based on trans-activation.

B K Felber1, G N Pavlakis.   

Abstract

A bioassay that is based on trans-activation has been developed for the detection and quantitation of the human immunodeficiency virus type 1 (HIV-1). Indicator cell lines were constructed that contain the HIV-1 long terminal repeat ligated to the chloramphenicol acetyltransferase (CAT) gene. Infection of these cells by HIV activates the expression of CAT protein. Isolates of HIV-1 with divergent nucleotide sequences activated the indicator cell lines to a similar extent, approximately 500- to 1000-fold. Human T cell lymphotropic viruses types 1 and 2, equine infectious anemia virus, and herpes simplex virus 1 did not activate the indicator cell lines. Isolates of simian immunodeficiency virus and human T cell lymphotropic virus type 4 activated these cells to a much lesser extent, which suggests that these viruses contain similar, but distinct, trans-activators. This assay can be used for the detection, quantitation, and typing of HIV and for studying the effect of drugs on the replication of HIV in different cellular backgrounds.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3422113     DOI: 10.1126/science.3422113

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  63 in total

1.  Human immunodeficiency virus type 1 tat protein activates transcription factor NF-kappaB through the cellular interferon-inducible, double-stranded RNA-dependent protein kinase, PKR.

Authors:  F Demarchi; M I Gutierrez; M Giacca
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

2.  Modulation of HIV transcription by CD8(+) cells is mediated via multiple elements of the long terminal repeat.

Authors:  D M Maslove; L W Ni; N C Hawley-Foss; A D Badley; K F Copeland
Journal:  Clin Exp Immunol       Date:  2001-07       Impact factor: 4.330

3.  Substance P antagonist (CP-96,345) inhibits HIV-1 replication in human mononuclear phagocytes.

Authors:  J P Lai; W Z Ho; G X Zhan; Y Yi; R G Collman; S D Douglas
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-27       Impact factor: 11.205

4.  Molecular dynamics simulations on HIV-1 Tat.

Authors:  Sergio Pantano; Mudit Tyagi; Mauro Giacca; Paolo Carloni
Journal:  Eur Biophys J       Date:  2003-11-08       Impact factor: 1.733

5.  Regulation of HIV-1 gene expression by histone acetylation and factor recruitment at the LTR promoter.

Authors:  Marina Lusic; Alessandro Marcello; Anna Cereseto; Mauro Giacca
Journal:  EMBO J       Date:  2003-12-15       Impact factor: 11.598

6.  Adenovirus expressing a bioluminescence reporter gene and cMAGI cell assay for the detection of HIV-1.

Authors:  Gadi Borkow; Humberto Herman Lara; Mila Ayash-Rashkovsky; Einat Tavor; Aviva Lapidot; Zvi Bentwich; Alik Honigman
Journal:  Virus Genes       Date:  2004-10       Impact factor: 2.332

7.  Generation and characterization of neutralizing human monoclonal antibodies against human immunodeficiency virus type 1 Tat antigen.

Authors:  Emmanuel Moreau; Johan Hoebeke; Daniel Zagury; Sylviane Muller; Claude Desgranges
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

8.  Rapid activation and subsequent down-regulation of the human immunodeficiency virus type 1 promoter in the presence of Tat: possible mechanisms contributing to latency.

Authors:  C M Drysdale; G N Pavlakis
Journal:  J Virol       Date:  1991-06       Impact factor: 5.103

9.  The role of Tat in the human immunodeficiency virus life cycle indicates a primary effect on transcriptional elongation.

Authors:  M B Feinberg; D Baltimore; A D Frankel
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-01       Impact factor: 11.205

10.  A novel action of minocycline: inhibition of human immunodeficiency virus type 1 infection in microglia.

Authors:  Qiusheng Si; Melissa Cosenza; Mee-Ohk Kim; Meng-Liang Zhao; Michael Brownlee; Harris Goldstein; Sunhee Lee
Journal:  J Neurovirol       Date:  2004-10       Impact factor: 2.643

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.